Trio have worked together for several years at different firms, bringing decades of experience in medical devices, robotics, ...

11 January 2022 Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune ...

Appeals board overturns previous decision and revokes patent on treatment worth $2bn in 2024 | Teva and Generics UK successful in arguing lack of inventive step. Already registered? If you don't have ...

David Gindler of Orrick discusses the US Supreme Court’s ruling in Amgen v. Sanofi and what it means for ongoing Section 112 litigation. The session considers how the decision has been applied – and ...

Despite efforts to harmonise, the Unified Patent Court’s local divisions and Court of Appeal have signalled a divergence over ...

4 February 2025 Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis ...

Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to ...

Former in-house counsel at major pharma companies brings expertise in IP strategy, regulatory compliance, and business ...

To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.

Ex-co-head of life sciences at previous firm brings expertise in multi-jurisdictional patent disputes involving supplementary ...

Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation ...

Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to ...